Daiichi Sankyo Co., Ltd.

Daiichi Sankyo Co., Ltd. logo
🇯🇵Japan
Ownership
Public
Established
2005-09-28
Employees
18.7K
Market Cap
-
Website
http://www.daiichisankyo.co.jp
Clinical Trials
Related News

Study of CS-3150 Compared to Olmesartan in Patients With Essential Hypertension

Not Applicable
Completed
Conditions
Essential Hypertension
Interventions
Drug: CS-3150
Drug: olmesartan medoxomil
First Posted Date
2016-07-28
Last Posted Date
2018-12-21
Lead Sponsor
Daiichi Sankyo Co., Ltd.
Target Recruit Count
40
Registration Number
NCT02848170

Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

First Posted Date
2016-07-15
Last Posted Date
2021-08-19
Lead Sponsor
Daiichi Sankyo Co., Ltd.
Target Recruit Count
7
Registration Number
NCT02834390

Study of CS-3150 in Combination With ARB or ACE Inhibitor in Hypertensive Patients With Moderate Renal Impairment

Phase 3
Completed
Conditions
Hypertension With Moderate Renal Impairment
Interventions
Drug: CS-3150
First Posted Date
2016-06-21
Last Posted Date
2018-12-21
Lead Sponsor
Daiichi Sankyo Co., Ltd.
Target Recruit Count
58
Registration Number
NCT02807987

Study of CS-3150 in Hypertensive Patients With Type 2 Diabetes and Albuminuria

Phase 3
Completed
Conditions
Hypertension
Interventions
Drug: CS-3150
First Posted Date
2016-06-21
Last Posted Date
2018-12-21
Lead Sponsor
Daiichi Sankyo Co., Ltd.
Target Recruit Count
51
Registration Number
NCT02807974

Study of CS-3150 in Patients With Severe Hypertension

Phase 3
Completed
Conditions
Severe Hypertension
Interventions
Drug: CS-3150
First Posted Date
2016-06-21
Last Posted Date
2018-12-21
Lead Sponsor
Daiichi Sankyo Co., Ltd.
Target Recruit Count
20
Registration Number
NCT02808026

Study of DU-176b Aged 80 Years or Older

Phase 3
Completed
Conditions
Atrial Fibrillation
Interventions
Drug: placebo
Drug: Du-176b
First Posted Date
2016-06-16
Last Posted Date
2020-11-19
Lead Sponsor
Daiichi Sankyo Co., Ltd.
Target Recruit Count
984
Registration Number
NCT02801669
Locations
🇯🇵

Gifu Heart Center, Gifu-city, Japan

🇯🇵

Tokyo Tenshi Hospital, Hachiōji-city, Japan

🇯🇵

National Hospital Organization Hamada Medical Center, Hamada-city, Japan

and more 161 locations

Study of Pexidartinib in Asian Subjects With Advanced Solid Tumors

Phase 1
Completed
Conditions
Advanced Solid Tumors
Interventions
Drug: Pexidartinib
First Posted Date
2016-04-12
Last Posted Date
2022-04-25
Lead Sponsor
Daiichi Sankyo Co., Ltd.
Target Recruit Count
12
Registration Number
NCT02734433

DS-3201b in Participants With Lymphomas

Phase 1
Active, not recruiting
Conditions
Lymphoma, Malignant
Non-hodgkin Lymphoma
Interventions
Drug: DS-3201b
First Posted Date
2016-04-08
Last Posted Date
2024-04-08
Lead Sponsor
Daiichi Sankyo Co., Ltd.
Target Recruit Count
100
Registration Number
NCT02732275
Locations
🇺🇸

The Ohio State University Wexner Medical Center and James Cancer Hospital, Columbus, Ohio, United States

🇺🇸

City of Hope National Medical center, Duarte, California, United States

🇺🇸

Emory University, Atlanta, Georgia, United States

and more 17 locations

Long-term Study of CS-3150 as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patients With Essential Hypertension

Phase 3
Completed
Conditions
Essential Hypertension
Interventions
Drug: CS-3150
First Posted Date
2016-03-29
Last Posted Date
2019-10-08
Lead Sponsor
Daiichi Sankyo Co., Ltd.
Target Recruit Count
368
Registration Number
NCT02722265

Study of DS-1123a in Advanced Solid Tumours

Phase 1
Completed
Conditions
Advanced Solid Malignant Tumors
Interventions
Drug: DS-1123
First Posted Date
2016-02-24
Last Posted Date
2018-12-24
Lead Sponsor
Daiichi Sankyo Co., Ltd.
Target Recruit Count
27
Registration Number
NCT02690337
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy